Table 3 CSF and plasma biomarkers’ sensitivity, specificity, and accuracy in distinguishing the major diagnostic categories
| Â | Analyte | Biosample | Cutoff (pg/ml) | Sens. (%) (95% CI) | Spec. (%) (95% CI) | AUC (95% CI) |
|---|---|---|---|---|---|---|
HC vs. disease groups | NfL | Plasma | > 16.6 | 76.9 (72.0–81.2) | 90.0 (79.9–95.3) | 0.897 (0.864–0.930) |
GFAP | Plasma | > 163.1 | 81.2 (76.5–85.1) | 85.0 (73.9–91.9) | 0.880 (0.846–0.915) | |
p-tau181 | Plasma | > 1.57 | 54.0 (48.5–59.5) | 86.7 (75.8–93.1) | 0.716 (0.658–0.774) | |
FTD vs. other diseasesa | NfL | CSF | > 1801 | 71.2 (58.6–81.2) | 78.6 (72.5–83.7) | 0.784 (0.710–0.857) |
Plasma | > 31.3 | 72.9 (60.4–82.6) | 74.3 (67.9–79.8) | 0.761 (0.686–0.836) | ||
AD vs. other diseasesb | p-tau181 | CSF | > 65.5 | 91.8 (84.6–95.8) | 90.5 (85.1–94.1) | 0.954 (0.931–0.978) |
Plasma | >1.98 | 86.6 (78.4–92.0) | 80.0 (73.3–85.4) | 0.889 (0.851–0.928) | ||
GFAP | CSF | > 7958 | 83.5 (74.9–89.6) | 34.5 (27.8–41.9) | 0.584 (0.514–0.653) | |
Plasma | > 313.6 | 73.2 (63.6–81.0) | 64.9 (57.4–71.7) | 0.703 (0.638–0.768) |